Thirty-three breast cancer patients underwent neoadjuvant chemotherapy, and therefore, were scanned for DW and DCE-MRI in the following three time-points: before NAT, after the first cycle of NAT, and after all NAT cycles. The gene discussed is BRD2; the disease is breast cancer.